Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
Rev. bras. hematol. hemoter
;
33(6): 470-475, Dec. 2011. tab
Article
Dans Anglais
| LILACS
| ID: lil-611385
ABSTRACT
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing high performance liquid chromatography and allele specific polymerase chain reaction. Mutation analysis has become mandatory during patient workup of chronic myeloid leukemia in order for the physician to choose the most suitable tyrosine kinase inhibitor. This article, a review of possible therapies used to overcome imatinib resistance, investigates the current position by searching the PubMed electronic database using the following keywords imatinib, dasatinib, nilotinib, aurora kinase, SRC kinase, mutation, treatment, drugs and resistance. New tyrosine kinase inhibitors include BCR-ABL kinase selective inhibitors, dual ABL/SRC kinase inhibitors and aurora kinase inhibitors. Awareness of the spectrum of new drugs against mutations, in particular the T315I mutation, makes it possible to properly select the best therapy for each patient.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Protein-tyrosine kinases
/
Résistance aux substances
/
Leucémie myéloïde chronique BCR-ABL positive
/
Tumeurs
/
Antinéoplasiques
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Rev. bras. hematol. hemoter
Thème du journal:
Hématologie
Année:
2011
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Instituto Nacional do Cancer/BR
/
Universidade Federal do Espírito Santo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS